GlassScriptPhysician profile
Anwar A Khan
NPI 1942268578
$10,611.52
in general payments reported to CMS, 2019-2025
45 companies · $690 in 2025
The $690 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,056 · 2020: $2,392 · 2021: $1,741 · 2022: $2,222 · 2023: $1,036 · 2024: $475 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,325.92 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,120.31 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $917.62 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $894.35 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $716.99 | 2019-2024 | Farxiga, Breztri |
| Amgen INC. | $679.80 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $631.68 | 2021-2025 | |
| Novo Nordisk INC | $473.39 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $405.84 | 2019-2022 | |
| Lilly USA, LLC | $402.73 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.90 | 2019-2025 | Jardiance, Ofev |
| Ironwood Pharmaceuticals, INC | $296.24 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $293.69 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $234.12 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $227.30 | 2019-2023 | Vaxneuvance, Pneumovax 23 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwar Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.